Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)

NCT05027074 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

506

Enrollment

INDUSTRY

Sponsor class

Conditions

End-Stage Renal Disease
End-Stage Kidney Disease
Kidney Failure, Chronic

Interventions

DRUG: MK-2060
DRUG: Placebo

Sponsor

Merck Sharp & Dohme LLC